143 related articles for article (PubMed ID: 9888524)
21. Inhibition by mibefradil, a novel calcium channel antagonist, of Ca(2+)- and volume-activated Cl- channels in macrovascular endothelial cells.
Nilius B; Prenen J; Kamouchi M; Viana F; Voets T; Droogmans G
Br J Pharmacol; 1997 Jun; 121(3):547-55. PubMed ID: 9179399
[TBL] [Abstract][Full Text] [Related]
22. Effects of Ca2+ channel blockers on Ca2+ loading induced by metabolic inhibition and hyperkalemia in cardiomyocytes.
Tang T; Duffield R; Ho AK
Eur J Pharmacol; 1998 Nov; 360(2-3):205-11. PubMed ID: 9851587
[TBL] [Abstract][Full Text] [Related]
23. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
Noll G; Lüscher TF
Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
[TBL] [Abstract][Full Text] [Related]
24. [Blocking of T-type calcium channels: new horizons in the therapeutic potential of calcium antagonists].
Cerqueira-Gomes M; Maciel MJ; Martins L
Rev Port Cardiol; 1998 Jan; 17(1):9-15. PubMed ID: 9558949
[No Abstract] [Full Text] [Related]
25. Blockade of receptor-operated calcium channels by mibefradil (Ro 40-5967): effects on intracellular calcium and platelet aggregation.
Hahn M; Tkachuk VA; Bochkov VN; Cheglakov IB; Clozel JP
Cardiovasc Drugs Ther; 1995 Dec; 9(6):815-21. PubMed ID: 8850387
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells.
Rossier MF; Ertel EA; Vallotton MB; Capponi AM
J Pharmacol Exp Ther; 1998 Dec; 287(3):824-31. PubMed ID: 9864260
[TBL] [Abstract][Full Text] [Related]
27. Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel.
Schmitt R; Clozel JP; Iberg N; Bühler FR
Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1161-5. PubMed ID: 7627710
[TBL] [Abstract][Full Text] [Related]
28. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms.
Lee TS; Kaku T; Takebayashi S; Uchino T; Miyamoto S; Hadama T; Perez-Reyes E; Ono K
Pharmacology; 2006; 78(1):11-20. PubMed ID: 16899990
[TBL] [Abstract][Full Text] [Related]
29. Proliferation of human peripheral blood mononuclear cells during calcium entry blockade. Role of protein kinase C.
Lijnen P; Petrov V
Methods Find Exp Clin Pharmacol; 1999 May; 21(4):253-9. PubMed ID: 10399131
[TBL] [Abstract][Full Text] [Related]
30. Potent vasodilatory with minor cardiodepressant actions of mibefradil in human cardiac tissue.
Brixius K; Mohr V; Müller-Ehmsen J; Hoischen S; Münch G; Schwinger RH
Br J Pharmacol; 1998 Sep; 125(1):41-8. PubMed ID: 9776342
[TBL] [Abstract][Full Text] [Related]
31. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists.
Sarsero D; Fujiwara T; Molenaar P; Angus JA
Br J Pharmacol; 1998 Sep; 125(1):109-19. PubMed ID: 9776350
[TBL] [Abstract][Full Text] [Related]
32. [Impact of calcium channel antagonists for estrogen action on the endometrial carcinoma HEC-1A cells].
Bao XX; Wang JL; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):212-7. PubMed ID: 22781074
[TBL] [Abstract][Full Text] [Related]
33. NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels.
Huang L; Keyser BM; Tagmose TM; Hansen JB; Taylor JT; Zhuang H; Zhang M; Ragsdale DS; Li M
J Pharmacol Exp Ther; 2004 Apr; 309(1):193-9. PubMed ID: 14718587
[TBL] [Abstract][Full Text] [Related]
34. Potential-dependent inhibition of cardiac Ca2+ inward currents by Ro 40-5967 and verapamil: relation to negative inotropy.
Fang LM; Osterrieder W
Eur J Pharmacol; 1991 Apr; 196(2):205-7. PubMed ID: 1651875
[TBL] [Abstract][Full Text] [Related]
35. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist.
Triggle DJ
Am J Cardiol; 1996 Nov; 78(9A):7-12. PubMed ID: 8903279
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats.
Nakamura Y; Ono H; Frohlich ED
Hypertension; 1999 Aug; 34(2):273-8. PubMed ID: 10454453
[TBL] [Abstract][Full Text] [Related]
38. The physiological and pharmacological significance of cardiovascular T-type, voltage-gated calcium channels.
Triggle DJ
Am J Hypertens; 1998 Apr; 11(4 Pt 3):80S-87S. PubMed ID: 9607371
[TBL] [Abstract][Full Text] [Related]
39. Properties of T-type calcium current in enkephalinergic neurones in guinea-pig hypothalamic slices.
Niespodziany I; Derambure P; Poulain P
Pflugers Arch; 1999 May; 437(6):871-80. PubMed ID: 10370065
[TBL] [Abstract][Full Text] [Related]
40. Mibefradil- and omega-conotoxin GVIA-induced inhibition of noradrenaline release from the sympathetic nerves of the human heart.
Göthert M; Molderings GJ
Naunyn Schmiedebergs Arch Pharmacol; 1997 Dec; 356(6):860-3. PubMed ID: 9453476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
